Two Sigma Securities’s Apimeds Pharmaceuticals US APUS Stock Holding History

Two Sigma Securities’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,055	Closed	-$18.9K	–	2547
2026 Q1	$18.9K	Buy	+1,055	New	+$17K	﹤0.01%	1378

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Two Sigma Securities's APUS Position: Q2 2026 in Review

Two Sigma Securities sold out of Apimeds Pharmaceuticals US (APUS) in Q2 2026, closing a stake of 1,055 shares — an estimated $18.9K sold.

Two Sigma Securities first reported a position in APUS in Q1 2026 and held it in 1 quarter. The position peaked at $18.9K in Q1 2026. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

Two Sigma Securities reported no remaining Apimeds Pharmaceuticals US position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 1,055 Apimeds Pharmaceuticals US shares in Q2 2026, an estimated $18.9K.
Two Sigma Securities first reported a position in Apimeds Pharmaceuticals US in Q1 2026 and held it in 1 quarter.
Two Sigma Securities's Apimeds Pharmaceuticals US position peaked at $18.9K in Q1 2026.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.